Intercept Pharmaceuticals, Inc.

Tocagen Inc.

Santarus, Inc.

Novmetapharma Co., Ltd.

Mingsight Pharmaceuticals, Inc.

Denovo Biopharma LLC

Nano Pharmasolutions, Inc.

Kay Olmstead

Douglas J Jolly

Harry E Gruber

Mark Pruzanski

Mitsuhiro Matono

Jeffrey Edwards

Leigh A MacConell

Tonya K Marmon

Richard Gail Lancaster

Masashi Kagihiro

Ikuko Taoka

Lise Eliot

David Shapiro

Roya Hooshmand-Rad

Richard Pencek

Cathi Sciacca

Warren Hall

David Pearson

Elaine McPherson

Gerald T Proehl

Julian Northen

Laura Jean Weston

Seok-Keun Koh

Saeyeon Lee

Laura Gallo

Elaine Mcpherson

Laura Weston

Craig Bowe

The present disclosure relates to various solid state forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine and methods of making the same. Such forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.

PKC inhibitor solid state forms

Provided herein is a coated particle comprising: (i) a microparticle that comprises a pharmaceutically acceptable excipient and (ii) nanoparticles of a therapeutic agent, wherein the surface of the microparticle is coated with the nanoparticles. Also provided herein is a pharmaceutical composition comprising the coated particle. Furthermore, provided herein are methods of their preparation.

Therapeutic agent nanoparticles and methods of preparation

The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) ('CHP').

Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease

The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.

Formulations of 5-fluorocytosine and uses thereof

The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.

Compositions of obeticholic acid and methods of use

Polymorphic forms of Cyclo (-His-Pro)

The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorouracil in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.

In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.

Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them

The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.

Growing community of inventors

San Diego, CA, United States of America

Kay Olmstead